INVERPHARMA LIMITED

Dissolved Bristol

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
I

INVERPHARMA LIMITED

Research and experimental development on biotechnology

Founded 20 Nov 2019 Dissolved Bristol, England 0 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 1 Apr 2025
Confirmation Submitted 19 Nov 2024 Next due 3 Dec 2025 6 months overdue
Net assets £-285 £98 2024 year on year
Total assets £115 £102 2024 year on year
Total Liabilities £400 £200 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

15 Frederick Place Bristol BS8 1AS England

Full company profile for INVERPHARMA LIMITED (12323303), a dissolved company based in Bristol, England. Incorporated 20 Nov 2019. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

N/A

Net Assets

-£285.00

Decreased by £98.00 (-52%)

Total Liabilities

£400.00

Increased by £200.00 (+100%)

Turnover

N/A

Employees

N/A

Debt Ratio

348%

Decreased by 1190 (-77%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 309 Shares £309 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
1 Mar 2025309£309£309

Officers

Officers

2 active
Status
Anthony Michael ParkerDirectorBritishEngland6420 Nov 2019Active
Richard TompkinsDirectorBritishUnited Kingdom5920 Nov 2019Active

Shareholders

Shareholders (1)

Argonaute Rna Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Argonaute Rna Limited

United Kingdom

Active
Notified 20 Nov 2019
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

ARGONAUTE RNA LIMITED united kingdom
INVERPHARMA LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
1 Jul 2025GazetteGazette Dissolved Voluntary
15 Apr 2025GazetteGazette Notice Voluntary
8 Apr 2025DissolutionDissolution Application Strike Off Company
1 Apr 2025CapitalAllotment of shares (GBP 409) on 1 Mar 2025
1 Apr 2025AccountsAnnual accounts made up to 30 Nov 2024
1 Jul 2025 Gazette

Gazette Dissolved Voluntary

15 Apr 2025 Gazette

Gazette Notice Voluntary

8 Apr 2025 Dissolution

Dissolution Application Strike Off Company

1 Apr 2025 Capital

Allotment of shares (GBP 409) on 1 Mar 2025

1 Apr 2025 Accounts

Annual accounts made up to 30 Nov 2024

Recent Activity

Latest Activity

Gazette Dissolved Voluntary

10 months ago on 1 Jul 2025

Gazette Notice Voluntary

1 years ago on 15 Apr 2025

Dissolution Application Strike Off Company

1 years ago on 8 Apr 2025

Allotment of shares (GBP 409) on 1 Mar 2025

1 years ago on 1 Apr 2025

Annual accounts made up to 30 Nov 2024

1 years ago on 1 Apr 2025